Transitory deficit in high-density lipoproteins and apolipoprotein A-I. 1990

B Legras, and C Clerc, and A Ruelland, and G Doualin, and V Fertil, and L Cloarec

UI MeSH Term Description Entries
D008075 Lipoproteins, HDL A class of lipoproteins of small size (4-13 nm) and dense (greater than 1.063 g/ml) particles. HDL lipoproteins, synthesized in the liver without a lipid core, accumulate cholesterol esters from peripheral tissues and transport them to the liver for re-utilization or elimination from the body (the reverse cholesterol transport). Their major protein component is APOLIPOPROTEIN A-I. HDL also shuttle APOLIPOPROTEINS C and APOLIPOPROTEINS E to and from triglyceride-rich lipoproteins during their catabolism. HDL plasma level has been inversely correlated with the risk of cardiovascular diseases. High Density Lipoprotein,High-Density Lipoprotein,High-Density Lipoproteins,alpha-Lipoprotein,alpha-Lipoproteins,Heavy Lipoproteins,alpha-1 Lipoprotein,Density Lipoprotein, High,HDL Lipoproteins,High Density Lipoproteins,Lipoprotein, High Density,Lipoprotein, High-Density,Lipoproteins, Heavy,Lipoproteins, High-Density,alpha Lipoprotein,alpha Lipoproteins
D008297 Male Males
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D011341 Probucol A drug used to lower LDL and HDL cholesterol yet has little effect on serum-triglyceride or VLDL cholesterol. (From Martindale, The Extra Pharmacopoeia, 30th ed, p993). Biphenabid,DH-581,Lorelco,Lurselle,Panavir,Superlipid,DH 581,DH581
D002995 Clofibric Acid An antilipemic agent that is the biologically active metabolite of CLOFIBRATE. Clofibrinic Acid,2-(4-Chlorophenoxy)-2-methylpropionic Acid,NSC-1149,p-Chlorophenoxyisobutyrate,p-Chlorophenoxyisobutyric Acid,NSC 1149,NSC1149
D004359 Drug Therapy, Combination Therapy with two or more separate preparations given for a combined effect. Combination Chemotherapy,Polychemotherapy,Chemotherapy, Combination,Combination Drug Therapy,Drug Polytherapy,Therapy, Combination Drug,Chemotherapies, Combination,Combination Chemotherapies,Combination Drug Therapies,Drug Polytherapies,Drug Therapies, Combination,Polychemotherapies,Polytherapies, Drug,Polytherapy, Drug,Therapies, Combination Drug
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000960 Hypolipidemic Agents Substances that lower the levels of certain LIPIDS in the BLOOD. They are used to treat HYPERLIPIDEMIAS. Antihyperlipidemic,Antilipemic,Antilipemic Agents,Antilipemic Drug,Hypolipidemic Agent,Hypolipidemic Drug,Antihyperlipemics,Antihyperlipidemics,Antilipemic Drugs,Antilipemics,Hypolipidemic Drugs,Agent, Hypolipidemic,Agents, Antilipemic,Agents, Hypolipidemic,Drug, Antilipemic,Drug, Hypolipidemic,Drugs, Antilipemic,Drugs, Hypolipidemic
D001054 Apolipoproteins A Structural proteins of the alpha-lipoproteins (HIGH DENSITY LIPOPROTEINS), including APOLIPOPROTEIN A-I and APOLIPOPROTEIN A-II. They can modulate the activity of LECITHIN CHOLESTEROL ACYLTRANSFERASE. These apolipoproteins are low in atherosclerotic patients. They are either absent or present in extremely low plasma concentration in TANGIER DISEASE. Apo-A,ApoA
D001629 Bezafibrate An antilipemic agent that lowers CHOLESTEROL and TRIGLYCERIDES. It decreases LOW DENSITY LIPOPROTEINS and increases HIGH DENSITY LIPOPROTEINS. Azufibrat,BM-15.075,Befibrat,Beza-Lande,Beza-Puren,Bezabeta,Bezacur,Bezafibrat PB,Bezafisal,Bezalip,Bezamerck,Béfizal,Cedur,Difaterol,Eulitop,Lipox,Reducterol,Regadrin B,Sklerofibrat,Solibay,durabezur,BM 15.075,BM15.075,Beza Lande,Beza Puren

Related Publications

B Legras, and C Clerc, and A Ruelland, and G Doualin, and V Fertil, and L Cloarec
August 2018, Arteriosclerosis, thrombosis, and vascular biology,
B Legras, and C Clerc, and A Ruelland, and G Doualin, and V Fertil, and L Cloarec
January 2000, Journal of lipid research,
B Legras, and C Clerc, and A Ruelland, and G Doualin, and V Fertil, and L Cloarec
August 2007, The Journal of biological chemistry,
B Legras, and C Clerc, and A Ruelland, and G Doualin, and V Fertil, and L Cloarec
September 1999, Journal of lipid research,
B Legras, and C Clerc, and A Ruelland, and G Doualin, and V Fertil, and L Cloarec
May 2023, Best practice & research. Clinical endocrinology & metabolism,
B Legras, and C Clerc, and A Ruelland, and G Doualin, and V Fertil, and L Cloarec
May 2018, Proceedings of the National Academy of Sciences of the United States of America,
B Legras, and C Clerc, and A Ruelland, and G Doualin, and V Fertil, and L Cloarec
February 2000, Chemistry and physics of lipids,
B Legras, and C Clerc, and A Ruelland, and G Doualin, and V Fertil, and L Cloarec
January 1996, Methods in enzymology,
B Legras, and C Clerc, and A Ruelland, and G Doualin, and V Fertil, and L Cloarec
March 2012, The Journal of biological chemistry,
B Legras, and C Clerc, and A Ruelland, and G Doualin, and V Fertil, and L Cloarec
January 2020, Sub-cellular biochemistry,
Copied contents to your clipboard!